Spark Therapeutics offers to cure blindness for $850,000

Published on: 04 Jan, 2018

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. Unlike some other treatments that require multiple therapies and steady payments, the Luxturna treatment will require only one treatment.

The company announced on their press release that they will be offering “outcome-based rebates and an innovative contracting model that support patient access in the U.S. while aiming to reduce risk and financial burden for payers and treatment centers.”

Spark Therapeutics has teamed with Express Scripts on distribution and pharmacy services for Luxturna. Dr. Steve Miller, chief medical officer of Express Scripts, agrees that the treatment iis very expensive, but believes the company has put it at a fair price range. "The product is just phenomenally innovative, and we've been talking about gene therapy for over 20 years. We're now at the threshold of having gene therapy reaching patients." says Miller.

The gene therapy targets a gene mutation called RPE65, which causes deteriorating vision over time. The treatment is performed by using a healthy copy of a gene to make up for the deficiency that the gene mutation causes.

The one time, outcome-based payment program could be a model for future one time treatments.

Ratings

Ratings
  • 1809Views
  • 0Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Nelson Cheng

Email: nelson@financialinsiders.com

@Newsletter

Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Related Posts

06 Jun, 2017 3425
14 Jul, 2017 2642
26 Jul, 2017 2797
08 Aug, 2017 2803

Comments

There is no comment on this article